CGEM

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 14, 2024
Research, EGFR, NSCLC, Disease, AML, Cullinan, Patient, Tissue, Sale, Multiple myeloma, G&A, CMC, Enrollment, IND, Lymph, Investment, MDS, FDA, Lymphoma, Spleen, CD19, CGEM, Pharmaceutical industry

CAMBRIDGE, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted oncology therapies, today reported on recent and upcoming business highlights and announced its financial results for the fourth quarter and full year ended December 31, 2023. The company also announced that Chief Financial Officer Jeff Trigilio will depart the company effective March 29. Following his departure, Jeff has agreed to support the company through a transition period.

Key Points: 
  • R&D Expenses: Research and development (R&D) expenses were $34.8 million for the fourth quarter of 2023, compared to $33.8 million for the third quarter of 2023.
  • R&D expenses for the fourth and third quarters of 2023 included $2.7 million and $3.2 million of equity-based compensation expenses, respectively.
  • G&A Expenses: General and administrative (G&A) expenses were $10.6 million for the fourth quarter of 2023, compared to $11.0 million for the third quarter of 2023.
  • Net Loss: Net loss (before items attributable to noncontrolling interest) for the fourth quarter of 2023 was $25.6 million, compared with net loss of $39.2 million for the third quarter of 2023.

Reviving Trade Ties: 135th Canton Fair Focuses on Strengthening Economic Bonds with Middle Eastern Nations

Retrieved on: 
Tuesday, March 19, 2024
Partnership, Electronics, Dubai World Trade Centre, Canton Fair, Commerce, CGEM, Audit

Led by Zhang Sihong, Deputy Secretary General of the Canton Fair and Deputy Director General of China Foreign Trade Centre, the delegation invited high-quality enterprises from the countries and surrounding regions, to explore cooperation and business opportunities, achieving remarkable outcomes.

Key Points: 
  • Led by Zhang Sihong, Deputy Secretary General of the Canton Fair and Deputy Director General of China Foreign Trade Centre, the delegation invited high-quality enterprises from the countries and surrounding regions, to explore cooperation and business opportunities, achieving remarkable outcomes.
  • In Morocco, China Foreign Trade Centre renewed its partnership agreement with Confédération Générale Des Entreprises Du Maroc (CGEM), further promoting trade between China and Morocco.
  • The 135th Canton Fair promotion tour has received an enthusiastic response from the three Middle Eastern countries, continuously revitalizing trade vitality in the local and surrounding regions.
  • For the latest information on the 135th Canton Fair, please register at https://invitation.cantonfair.org.cn/BuyerUser/RegisterUser?MediaType=16 .

Reviving Trade Ties: 135th Canton Fair Focuses on Strengthening Economic Bonds with Middle Eastern Nations

Retrieved on: 
Tuesday, March 19, 2024
Partnership, Electronics, Dubai World Trade Centre, Canton Fair, Commerce, Multimedia, CGEM

Led by Zhang Sihong, Deputy Secretary General of the Canton Fair and Deputy Director General of China Foreign Trade Centre, the delegation invited high-quality enterprises from the countries and surrounding regions, to explore cooperation and business opportunities, achieving remarkable outcomes.

Key Points: 
  • Led by Zhang Sihong, Deputy Secretary General of the Canton Fair and Deputy Director General of China Foreign Trade Centre, the delegation invited high-quality enterprises from the countries and surrounding regions, to explore cooperation and business opportunities, achieving remarkable outcomes.
  • In Morocco, China Foreign Trade Centre renewed its partnership agreement with Confédération Générale Des Entreprises Du Maroc (CGEM), further promoting trade between China and Morocco.
  • The 135th Canton Fair promotion tour has received an enthusiastic response from the three Middle Eastern countries, continuously revitalizing trade vitality in the local and surrounding regions.
  • For the latest information on the 135th Canton Fair, please register at https://invitation.cantonfair.org.cn/BuyerUser/RegisterUser?MediaType=16 .

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma

Retrieved on: 
Friday, March 1, 2024
CGEM, Escape Room, FDA, Food, SITC, MBA, MICA, Bone marrow, Immunoglobulin G, MICB, Malignancy, Patient, MPH, Multiple myeloma, IND, Trial of the century, Vaccine

CAMBRIDGE, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for CLN-619 in relapsed/refractory multiple myeloma. CLN-619 is a potential first-in-class humanized IgG1 monoclonal antibody that binds to stress-induced ligands, MICA and MICB, which are expressed on a wide variety of solid tumors and hematologic malignancies. The company will commence a Phase 1 dose-escalation and dose-expansion trial of CLN-619.

Key Points: 
  • The company will commence a Phase 1 dose-escalation and dose-expansion trial of CLN-619.
  • “Multiple myeloma remains incurable, and most patients experience sequential relapses.
  • The response to treatment is typically shorter with each relapse, so novel treatments are still needed,” said Jeffrey Jones, MD, MPH, MBA, Chief Medical Officer, Cullinan Oncology.
  • “Multiple myeloma is another example of a malignancy where MICA/B shedding from tumor cells allows for immune evasion.

Cullinan Oncology to Participate in Upcoming Investor Conferences

Retrieved on: 
Tuesday, February 27, 2024
CGEM, Gynecologic oncology, Panel discussion, Conference

CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced its participation in the following upcoming investor conferences:

Key Points: 
  • CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced its participation in the following upcoming investor conferences:
    Jeffrey Jones, M.D., M.P.H., M.B.A., Chief Medical Officer, will participate in a Panel Discussion on Gynecologic Cancers at the TD Cowen 44th Annual Health Care Conference in Boston, MA on Tuesday, March 5, 2024, at 10:30 AM ET.
  • Jeff Trigilio, Chief Financial Officer, will participate in a fireside chat at the Leerink Partners Global Biopharma Conference in Miami, FL on Wednesday, March 13, 2024, at 8:00 AM ET.

Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, December 18, 2023
PST, EST, Conference, CGEM

CAMBRIDGE, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) --  Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that Chief Executive Officer, Nadim Ahmed, will present at the 42nd Annual J.P. Morgan Healthcare Conference, being held January 8-11, 2024 in San Francisco, CA.

Key Points: 
  • CAMBRIDGE, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) --  Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that Chief Executive Officer, Nadim Ahmed, will present at the 42nd Annual J.P. Morgan Healthcare Conference, being held January 8-11, 2024 in San Francisco, CA.
  • Mr. Ahmed’s presentation is scheduled for Thursday, January 11, at 10:30 am PST (1:30 pm EST).

Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines

Retrieved on: 
Thursday, December 14, 2023
Cytokine, Neoplasm, Survival, PD-1, MBA, Pharmacokinetics, PD, CGEM, MPH, Patient, Safety, Pembrolizumab

CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic, targeted oncology therapies, today announced that the first patient has been dosed with CLN-617 in a Phase 1 clinical trial.

Key Points: 
  • CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic, targeted oncology therapies, today announced that the first patient has been dosed with CLN-617 in a Phase 1 clinical trial.
  • “CLN-617 is a first-in-class cytokine therapy uniquely combining human IL-2, IL-12, a collagen binding domain, and a size-enhancing domain in a single molecule designed for intratumoral injection.
  • These unique characteristics are intended to promote retention of the cytokines in the injected tumor and potentially provide enhanced safety and efficacy.
  • We look forward to working with investigators to explore the potential of CLN-617, Cullinan Oncology’s sixth program in clinical development.”

Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Wednesday, November 8, 2023
Research, NSCLC, Non-small-cell lung cancer, CD19, Pembrolizumab, G&A, Cullinan, R, D, Disease, Neoplasm, CGEM, Annual general meeting, Investment, Chemistry, Patient, EGFR, Nursing, Pharmaceutical industry, Medical imaging, Vaccine, Taiho

CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM; “Cullinan”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today reported on recent and upcoming business highlights and announced its financial results for the third quarter ended September 30, 2023.

Key Points: 
  • “We have made tremendous strides through the first three quarters of 2023, while positioning Cullinan for a data-rich 2024,” said Nadim Ahmed, Chief Executive Officer of Cullinan Oncology.
  • R&D Expenses: Research and development (R&D) expenses were $33.8 million for the third quarter of 2023, compared to $27.4 million for the second quarter of 2023.
  • G&A Expenses: General and administrative (G&A) expenses were $11.0 million for the third quarter of 2023, compared to $10.2 million for the second quarter of 2023.
  • Net Loss: Net loss (before items attributable to noncontrolling interest) for the third quarter of 2023 was $39.2 million, compared with net loss of $32.2 million for the second quarter of 2023.

Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023

Retrieved on: 
Friday, November 3, 2023
Neoplasm, MSS, Society for Immunotherapy of Cancer, CD19, Pembrolizumab, Endometrial cancer, Cytokine, Pharmacokinetics, SITC, Immunotherapy, NK, CGEM, Biopsy, Annual general meeting, Safety, Society, Patient, MICA, Pharmaceutical industry, Vaccine, Medical imaging

CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (NASDAQ: CGEM) (“Cullinan”), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that it will present data across four distinct immuno-oncology programs in five poster presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting taking place November 1-5 in San Diego.

Key Points: 
  • “We are proud to showcase progress of our diversified pipeline at SITC 2023, where we will present data across multiple targets, mechanisms, and modalities,” said Jennifer Michaelson, Ph.D., Chief Scientific Officer of Cullinan Oncology.
  • Data from patients with available biopsy data demonstrate clinical benefit, including objective response, in patients with tumors with characteristics not typically responsive to checkpoint inhibitor therapy.
  • Specifically, tumors from two patients with endometrial cancer and previously reported confirmed partial responses were microsatellite stable (MSS), had low tumor mutational burden, and low neoantigen presentation index.
  • Available biopsies from patients with prolonged stable disease showed similar low mutational burden and neoantigen presentation index characteristics, as well as increased surface MICA/B expression and NK cell activation.

Cullinan Oncology to Participate in Upcoming Investor Conferences

Retrieved on: 
Monday, October 30, 2023
Evercore, Conference, CGEM, TD

CAMBRIDGE, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced its participation in the following upcoming investor conferences:

Key Points: 
  • CAMBRIDGE, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced its participation in the following upcoming investor conferences:
    Jeffrey Jones, M.D., M.P.H., M.B.A., Chief Medical Officer, and Jeff Trigilio, Chief Financial Officer will participate in a virtual fireside chat at the TD Cowen 7th Annual Fall Oncology Innovation Summit on Friday, November 3, 2023 at 1:30 PM ET.
  • Nadim Ahmed, Chief Executive Officer, will present at the Stifel 2023 Healthcare Conference in New York, NY on Tuesday, November 14, 2023, at 3:35 PM ET.
  • Nadim Ahmed, Chief Executive Officer, will participate in a fireside chat at the Evercore ISI HealthCONx Conference in Miami, FL on Thursday, November 30, 2023, at 8:20 AM ET.